Aisling Capital Management LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 12, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$299.3M2026 Q3
Positions14
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.98.5%
Top Holdings
BBIO
BridgeBio Pharma
67.9%
SNDX
Syndax Pharmaceuticals
8.3%
CMPS
COMPASS Pathways
7.2%
GLUE
Monte Rosa Therapeutics
6.2%
BCAX
Bicara Therapeutics
3.4%
URGN
UroGen Pharma
1.5%
BBOT
BridgeBio Oncology Therapeutics
1.4%
EPRX
Eupraxia Pharmaceuticals
1.0%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.